dilazep has been researched along with Acute Promyelocytic Leukemia in 1 studies
Dilazep: Coronary vasodilator with some antiarrhythmic activity.
dilazep : A member of the class of diazepanes that is 1,4-diazepane substituted by 3-[(3,4,5-trimethoxybenzoyl)oxy]propyl groups at positions 1 and 4. It is a potent adenosine uptake inhibitor that exhibits antiplatelet, antianginal and vasodilator properties.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cass, CE | 1 |
| King, KM | 1 |
| Montaño, JT | 1 |
| Janowska-Wieczorek, A | 1 |
1 other study available for dilazep and Acute Promyelocytic Leukemia
| Article | Year |
|---|---|
A comparison of the abilities of nitrobenzylthioinosine, dilazep, and dipyridamole to protect human hematopoietic cells from 7-deazaadenosine (tubercidin).
Topics: Adenosine; Colony-Forming Units Assay; Dilazep; Dipyridamole; Hematopoietic Stem Cells; Humans; Leuk | 1992 |